Skip to main content

Research Repository

Advanced Search

high INtensity Interval Training In pATiEnts with intermittent claudication (INITIATE): protocol for a multi-centre, proof-of-concept, prospective interventional study (2020)
Journal Article
Pymer, S., Harwood, A., Ibeggazene, S., McGregor, G., Huang, C., Twiddy, M., …Chetter, I. C. (2020). high INtensity Interval Training In pATiEnts with intermittent claudication (INITIATE): protocol for a multi-centre, proof-of-concept, prospective interventional study. BMJ open, 10(7), https://doi.org/10.1136/bmjopen-2020-038825

Introduction: The first-line recommended treatment for patients with intermittent claudication (IC), is a supervised exercise programme (SEP), which includes a minimum of 2 hours exercise per week over a 12-week period. However, provision, uptake, an... Read More about high INtensity Interval Training In pATiEnts with intermittent claudication (INITIATE): protocol for a multi-centre, proof-of-concept, prospective interventional study.

The effects of the iPlayClean education programme on doping attitudes and susceptibility to use banned substances among high-level adolescent athletes from the UK: A cluster-randomised controlled trial (2020)
Journal Article
Thompson, M. A., Morley, D., Abt, G., Nicholls, A. R., Rothwell, M., Cope, E., …Huang, C. (2020). The effects of the iPlayClean education programme on doping attitudes and susceptibility to use banned substances among high-level adolescent athletes from the UK: A cluster-randomised controlled trial. International Journal of Drug Policy, 82, https://doi.org/10.1016/j.drugpo.2020.102820

Background: This study examined the effects of the iPlayClean anti-doping intervention on attitudes towards doping and susceptibility, and whether delivery mode affected the results. Methods: A total of 1,081 high-level UK athletes (14-18 years old... Read More about The effects of the iPlayClean education programme on doping attitudes and susceptibility to use banned substances among high-level adolescent athletes from the UK: A cluster-randomised controlled trial.

The Effects of the iPlayClean Education Programme on Doping Attitudes and Susceptibility to use Banned Substances among High-Level Adolescent Athletes from the UK: A Cluster-Randomised Control Trial (2020)
Journal Article
Nicholls, A., Morley, D., Thompson, M. A., Huang, C., Abt, G., Rothwell, M., …Ntoumanis, N. (in press). The Effects of the iPlayClean Education Programme on Doping Attitudes and Susceptibility to use Banned Substances among High-Level Adolescent Athletes from the UK: A Cluster-Randomised Control Trial. International Journal of Drug Policy,

Background: This study examined the effects of the iPlayClean anti-doping intervention on attitudes towards doping and susceptibility, and whether delivery mode affected the results. Methods: A total of 1,081 high-level UK athletes (14-18 years old... Read More about The Effects of the iPlayClean Education Programme on Doping Attitudes and Susceptibility to use Banned Substances among High-Level Adolescent Athletes from the UK: A Cluster-Randomised Control Trial.

A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin (2020)
Journal Article
Jones, R., Crabb, S., Chester, J., Elliott, T., Huddart, R., Birtle, A., …Griffiths, G. (2020). A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin. BJU international, 126(2), 292-299. https://doi.org/10.1111/bju.15096

Objectives To assess the efficacy and tolerability of the dual epidermal growth factor receptor/vascular endothelial growth factor receptor inhibitor, vandetanib, in combination with carboplatin and gemcitabine in the first‐line treatment of patient... Read More about A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.

Presurgery conditioning interventions (prehabilitation) in adults undergoing lower limb surgery for peripheral arterial disease (2019)
Journal Article
Smith, G. E., Palmer, J., Pymer, S., Smith, G. E., Harwood, A. E., Ingle, L., …Chetter, I. C. (2019). Presurgery conditioning interventions (prehabilitation) in adults undergoing lower limb surgery for peripheral arterial disease. The Cochrane database of systematic reviews, 2019(9), https://doi.org/10.1002/14651858.cd013407

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effectiveness of prehabilitation (preoperative exercise, either alone or in combination with nutritional or psychological interventions or both)... Read More about Presurgery conditioning interventions (prehabilitation) in adults undergoing lower limb surgery for peripheral arterial disease.

The effectiveness of an intervention to reduce alcohol-related violence in premises licensed for the sale and on-site consumption of alcohol: a randomized controlled trial (2017)
Journal Article
Moore, S. C., Alam, M. F., Heikkinen, M., Hood, K., Huang, C., Moore, L., …Williams, A. (2017). The effectiveness of an intervention to reduce alcohol-related violence in premises licensed for the sale and on-site consumption of alcohol: a randomized controlled trial. Addiction, 112(11), 1898-1906. https://doi.org/10.1111/add.13878

Background and Aims: Premises licensed for the sale and consumption of alcohol can contribute to levels of assault-related injury through poor operational practices that, if addressed, could reduce violence. We tested the real-world effectiveness of... Read More about The effectiveness of an intervention to reduce alcohol-related violence in premises licensed for the sale and on-site consumption of alcohol: a randomized controlled trial.

Ignorability for general longitudinal data (2017)
Journal Article
Farewell, D. M., Huang, C., & Didelez, V. (2017). Ignorability for general longitudinal data. Biometrika, 104(2), 317-326. https://doi.org/10.1093/biomet/asx020

Likelihood factors that can be disregarded for inference are termed ignorable. We demonstrate that close ties exist between ignorability and identification of causal effects by covariate adjustment. A graphical condition, stability, plays a role anal... Read More about Ignorability for general longitudinal data.

A calibration method for non-positive definite covariance matrix in multivariate data analysis (2017)
Journal Article
Huang, C., Farewell, D., & Pan, J. (2017). A calibration method for non-positive definite covariance matrix in multivariate data analysis. Journal of Multivariate Analysis, 157, 45-52. https://doi.org/10.1016/j.jmva.2017.03.001

Covariance matrices that fail to be positive definite arise often in covariance estimation. Approaches addressing this problem exist, but are not well supported theoretically. In this paper, we propose a unified statistical and numerical matrix calib... Read More about A calibration method for non-positive definite covariance matrix in multivariate data analysis.

TOUCAN: A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin. (2016)
Journal Article
Jones, R. J., Crabb, S. J., Chester, J. D., Elliott, T., Huddart, R. A., Birtle, A. J., …Griffiths, G. (2016). TOUCAN: A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin. Journal of Clinical Oncology, 34(2_suppl), 448-448. https://doi.org/10.1200/jco.2016.34.2_suppl.448

Background: Whilst cisplatin combination therapy remains the standard of care for patients with advanced urothelial cancers, many patients are unsuitable for cisplatin and go on to receive carboplatin combination therapy. Although responses are frequ... Read More about TOUCAN: A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin..